Opinion
The company’s vaccine controversy could cause legal and image problems for years to come.
A look at what three ex-Genentech employees have accomplished at Denali so far.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
One of the biggest concerns has been the loss of the R&D tax credit, which incentivizes companies, including life science firms, to support research.
With Sage’s positive data, we may be embarking on a neuroscience renaissance.
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
The “singularity” is a term favored by futurists like Google exec Ray Kurzweill, typically in reference to computer technology.
A look at the FDA’s long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells.
Sage Therapeutics has been on a roll with good news lately.